Carmustine 100 IV Infusion100mg/vial

• Brain tumors (glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, metastatic brain tumors)
• Multiple myeloma (in combination with prednisone)
• Relapsed or refractory Hodgkin's lymphoma
• Relapsed or refractory non-Hodgkin's lymphoma

Adults (Single agent): 150-200 mg/m² IV every 6 weeks (as a single dose or divided into 2 consecutive days at 75-100 mg/m²).

Combination therapy or reduced bone marrow reserve: Dose adjustment required.

Administration: Reconstituted solution should be administered as a slow IV infusion over at least 2 hours.

Pediatric: Safety and effectiveness in children have not been established.

Geriatric: Dose selection should be cautious, usually starting at the low end of the dose range.

Common (>1%): Nausea, vomiting, renal toxicity, pneumonitis, pulmonary toxicity, myelosuppression (bone marrow suppression).

Pulmonary fibrosis: Delayed-onset pulmonary fibrosis may occur up to 17 years after treatment (especially in patients treated at <5 years of age).

Other: Nephrotoxicity, ocular toxicity (with unapproved intraarterial intracarotid route), carcinogenicity (potentially carcinogenic to humans).

• Monitor infusion site closely during administration to prevent extravasation.
• Potentially carcinogenic to humans; monitor patients periodically and inform them of symptoms to seek medical help.
• Ocular toxicity has occurred with unapproved intraarterial intracarotid route.
• Embryo-fetal toxicity: Can cause fetal harm; advise females of reproductive potential of potential risk and to avoid pregnancy.
• Elderly patients are more likely to have decreased renal function; monitor renal function and select dose cautiously.
• Do not use during pregnancy and lactation (Category D).